Hemin is currently used in the treatment of acute intermittent porphyria (AIP), a rare inherited metabolic disorder characterized by a deficiency in porphobilinogen deaminase, which disrupts heme biosynthesis [31]. This evidence concerns the gene HMBS and metabolic disease.